Actavis

  • Watson in talks to buy Actavis

    Watson Pharmaceuticals is currently in talks to buy private Swiss generic drug maker Actavis.

    Actavis | 11 May 2012

  • Actavis Opens Beijing Office

    Actavis has established a regional office for China at Beijing's Youth Plaza Office Building. The office will primarily handle registrations for imported products and related regulatory issues, as well as sales activities. It will be responsible f…

    Actavis | 20 May 2010

  • Actavis Divests Norgesplaster

    Actavis Group has sold Norgesplaster, its manufacturing facility for plasters and athletic tape and adhesive coating, in Vennesla, Norway, to a Norgesplaster AS. Norgesplaster AS is a legal entity that is owned by private Norwegian investors. The tra…

    Actavis | 11 February 2010

  • Actavis Launches High Blood Pressure Drug

    Actavis Group has announced the launch of Lercanidipine in five European countries. The drug is mainly used to treat high blood pressure. The company launched the product under its own brand name on day one in the UK and France, where the patents…

    Actavis | 04 February 2010

  • Actavis: Launch of Cholesterol Drug in Spain

    Actavis Group has announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market, according to…

    Actavis | 01 November 2009

  • Actavis: First to Market Drug in UK, Holland

    Actavis Group has announced the launch of Fluvastatin SR in the UK and the Netherlands. It is first to market the drug in both countries, according to the company. The tablets are the generic equivalent of Novartis' Luvinsta SR / Lescol XL and are…

    Actavis | 17 April 2009

  • Actavis and ASKA Establish Company in Japan

    Actavis Group and ASKA Pharmaceutical have signed an agreement to establish Actavis ASKA KK. The latter will hold 55 percent of shares in the joint venture, while the former will own 45 percent. The joint company will enter the Japanese generic pharm…

    Actavis | 30 March 2009

  • Actavis Acquires Kadian

    Actavis has acquired the brandname drug Kadian from King Pharmaceuticals for not more than $127.5 million. The drug is an extended release morphine sulfate product, and is the first originator brand product to be marketed by Actavis US. The compa…

    Actavis | 05 January 2009

  • Actavis Totowa and FDA Reach Agreement

    Actavis has reached an agreement on a Consent Decree of Permanent Injunction with the Food and Drug Administration (FDA) regarding the company's Actavis Totowa subsidiary. This agreement, in effect, settles the issues identified by the Department…

    Actavis | 02 January 2009

  • Actavis Restructures Operations in Bulgaria

    The Actavis Group has signed a letter of intent to sell its manufacturing subsidiary in Bulgaria "Balkanpharma-Razgrad AD" to a newly formed company "Antibiotic-Razgrad AD". The new company has been set up by representatives of current management at …

    Actavis | 18 December 2008

Page 1 Next > Last >>